Major deals continue positive trajectory for psychedelics in 2024 [Psychedelic Health]
Thursday, May 16, 2024 1 min read
Key Takeaway: The psychedelics market is experiencing significant growth in 2024, highlighted by major developments such as AbbVie's entry into the sector and a substantial $66.5 million deal between Enveric and MindBio. These events indicate a positive trajectory for innovative medicines in this field as the year unfolds.
Price reaction · baseline $146.61 (2024-05-16T16:37:00.000Z) · hit during market hours · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+10.5%
day 1
+3.1%
day 3
+1.7%
Market Sentiment Analysis
POSITIVE FACTORS
Psychedelics are gaining traction in 2024.
AbbVie, a major pharmaceutical company, is entering the market.
Enveric and MindBio secured a significant $66.5 million deal.
Full Press Release Details
Psychedelics started 2024 with a bang, and the innovative medicines are continuing to gain traction as the year progresses. This week saw one of the globe’s top five biggest pharmaceutical companies – AbbVie – enter the market, while Enveric and MindBio signed a $66.5 million deal.
Full Article >>
Frequently Asked Questions
What major company entered the psychedelics market in 2024?
AbbVie, one of the world's largest pharmaceutical companies, entered the market.
What deal did Enveric and MindBio sign?
Enveric and MindBio signed a significant deal worth $66.5 million.
How is the psychedelics market performing in 2024?
The psychedelics market is gaining traction and experiencing significant growth.